Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–6. https://doi.org/10.1038/ng1161.

Article  CAS  PubMed  Google Scholar 

Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–5. https://doi.org/10.1038/ng1509.

Article  CAS  PubMed  Google Scholar 

Lambert G, Sjouke B, Choque B, Kastelein JJP, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53(12):2515–24. https://doi.org/10.1194/jlr.R026658.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. J Clin Invest. 2006;116(11):2995–3005. https://doi.org/10.1172/JCI29383.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA. 2004;101(18):7100–5. https://doi.org/10.1073/pnas.0402133101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, et al. Cardiovascular efficacy and safety of Bococizumab in high-risk patients. N Engl J Med. 2017;376(16):1527–39. https://doi.org/10.1056/NEJMoa1701488.

Article  CAS  PubMed  Google Scholar 

Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36(36):2415–24. https://doi.org/10.1093/eurheartj/ehv174.

Article  CAS  PubMed  Google Scholar 

Roth EM, Taskinen M-R, Ginsberg HN, Kastelein JJP, Colhoun HM, Robinson JG, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014;176(1):55–61. https://doi.org/10.1016/j.ijcard.2014.06.049.

Article  PubMed  Google Scholar 

Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-915.e13. https://doi.org/10.1016/j.ahj.2015.03.004.

Article  CAS  PubMed  Google Scholar 

Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186–94. https://doi.org/10.1093/eurheartj/ehv028.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–9. https://doi.org/10.1056/NEJMoa1500858.

Article  CAS  PubMed  Google Scholar 

Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–19. https://doi.org/10.1056/NEJMoa1316222.

Article  CAS  PubMed  Google Scholar 

Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870. https://doi.org/10.1001/jama.2014.4030.

Article  CAS  PubMed  Google Scholar 

Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance. J Am Coll Cardiol. 2014;63(23):2541–8. https://doi.org/10.1016/j.jacc.2014.03.019.

Article  CAS  PubMed  Google Scholar 

Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-PCSK9 Monotherapy for Hypercholesterolemia. J Am Coll Cardiol. 2014;63(23):2531–40. https://doi.org/10.1016/j.jacc.2014.03.018.

Article  CAS  PubMed  Google Scholar 

Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D, RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–40. https://doi.org/10.1016/S0140-6736(14)61399-4. Epub 2014 Oct 1 PMID: 25282519.

Article  CAS  PubMed  Google Scholar 

Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA, TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341–50. https://doi.org/10.1016/S0140-6736(14)61374-X.

Article  CAS  PubMed  Google Scholar 

Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. ATVB. 2004;24(8):1454–9. https://doi.org/10.1161/01.ATV.0000134621.14315.43.

Article  CAS  Google Scholar 

Taylor BA, Thompson PD. Statins and their effect on PCSK9-impact and clinical relevance. Curr Atheroscler Rep. 2016;18(8):46. https://doi.org/10.1007/s11883-016-0604-3.

Article  CAS  PubMed  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. https://doi.org/10.1056/NEJMoa1615664.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373. https://doi.org/10.1001/jama.2016.16951.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ, Nissen SE, Prati F, Windecker S, Kataoka Y, Puri R, et al. Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovasc Diagn Ther. 2021;11(1):120–9. https://doi.org/10.21037/cdt-20-684.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107. https://doi.org/10.1056/NEJMoa1801174.

Article  CAS  PubMed  Google Scholar 

Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Sustained low-density lipoprotein cholesterol lowering with alirocumab in ODYSSEY OUTCOMES. J Am Coll Cardiol. 2020;75(4):448–51. https://doi.org/10.1016/j.jacc.2019.11.030.

Article  CAS  PubMed  Google Scholar 

Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault M-F, Dalby AJ, et al. Effect of alirocumab on mortality after acute coronary syndromes: an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation. 2019;140(2):103–12. https://doi.org/10.1161/CIRCULATIONAHA.118.038840.

Article  CAS  PubMed  PubMed Central